Similar articles

• Hemolytic uremic syndrome surveillance to monitor trends in infection with Escherichia coli O157:H7 and other shiga toxin-producing E. coli.

  Mahon BE, Griffin PM, Mead PS, Tauxe RV. Mahon BE, et al. Emerg Infect Dis. 1997 Jul-Sep;3(3):409-12. doi: 10.3201/eid0303.970329. Emerg Infect Dis. 1997. PMID: 9284395 Free PMC article. Review. No abstract available.
• [Enterohemorrhagic Escherichia coli--infection and a hemolytic uremic syndrome].

  Helminen M, Wisakanto KL, Raisio M, Baer M. Helminen M, et al. Duodecim. 1998;114(3):229-32. Duodecim. 1998. PMID: 10895492 Finnish. No abstract available.
• Hemolytic uremic syndrome: an emerging health risk.

  Razzaq S. Razzaq S. Am Fam Physician. 2006 Sep 15;74(6):991-6. Am Fam Physician. 2006. PMID: 17002034 Review.
• The emerging clinical importance of non-O157 Shiga toxin-producing Escherichia coli.

  Johnson KE, Thorpe CM, Sears CL. Johnson KE, et al. Clin Infect Dis. 2006 Dec 15;43(12):1587-95. doi: 10.1086/509573. Epub 2006 Nov 9. Clin Infect Dis. 2006. PMID: 17109294
• Relative nephroprotection during Escherichia coli O157:H7 infections: association with intravenous volume expansion.

  Ake JA, Jelacic S, Ciol MA, Watkins SL, Murray KF, Christie DL, Klein EJ, Tarr PI. Ake JA, et al. Pediatrics. 2005 Jun;115(6):e673-80. doi: 10.1542/peds.2004-2236. Pediatrics. 2005. PMID: 15930195